GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Dalfampridine (Ampyra)

GlobalRPh source pageBase record retrieved 2026-09-05See the evidence for this drug1 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Historical source

Original GlobalRPh source

Product / population
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

Usual Dosing (Adults)

AMPYRA is a potassium-channel blocker for improvement of walking in multiple sclerosis, demonstrated by increased walking speed. Maximum 10 mg twice daily approximately 12 hours apart, with or without food. Do not take extra/double doses for a missed dose. Higher doses showed no additional benefit and more adverse events including seizures. Take tablets whole; do not divide, crush, chew or dissolve. Strength: 10 mg tablets.

Renal Dosing

Contraindicated in moderate or severe renal impairment. In mild impairment (CrCl 51 to 80 mL/min), seizure risk is unknown, but exposure may approach that at 15 mg twice daily, which may increase seizures. Know estimated CrCl before starting treatment.

Hemodialysis

Contraindicated. Do not use.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/dalfampridine-ampyra/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/dalfampridine-ampyra/

Usual Dosing (Adults)

AMPYRA is a potassium-channel blocker for improvement of walking in multiple sclerosis, demonstrated by increased walking speed. Maximum 10 mg twice daily approximately 12 hours apart, with or without food. Do not take extra/double doses for a missed dose. Higher doses showed no additional benefit and more adverse events including seizures. Take tablets whole; do not divide, crush, chew or dissolve. Strength: 10 mg tablets.

GRPH-dalfampridine-ampyra-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Contraindicated in moderate or severe renal impairment. In mild impairment (CrCl 51 to 80 mL/min), seizure risk is unknown, but exposure may approach that at 15 mg twice daily, which may increase seizures. Know estimated CrCl before starting treatment.

GRPH-dalfampridine-ampyra-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Contraindicated. Do not use.

GRPH-dalfampridine-ampyra-03 · Source section: HemodialysisRenal section finder

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/dalfampridine-ampyra/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
c72ec21e48b5651e90b2394bf28ce8ace5dac6f89bde3bb677bcf14714023979
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report